Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy
暂无分享,去创建一个
J. Sparano | Yu Lin | J. Condeelis | T. D’alfonso | D. Entenberg | Saeed Asiry | M. Oktay | P. Ginter | E. Cheng | X. Xue | X. Ye | Gina Kim | J. Pastoriza | J. Qin | Nurfiza Ladak | V. Sharma | Burcu Karadal-Ferrena | Isabelle Oktay | Esther H. Adler | Xiaonan Xue
[1] A. Bianchi,et al. Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy , 2022, npj Breast Cancer.
[2] Q. Sun,et al. The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.
[3] T. Julian,et al. Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials , 2022, Cancer.
[4] T. Rohan,et al. Combining TMEM Doorway Score and MenaCalc Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients , 2022, Cancers.
[5] D. Esposito,et al. Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination , 2021, Nature Communications.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] J. Olson,et al. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. , 2020, Journal of the National Cancer Institute.
[8] T. Rohan,et al. Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis , 2020, Cancers.
[9] Hung-Ming Wang,et al. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer , 2019, BMC Cancer.
[10] Ahmedin Jemal,et al. Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[11] J. Condeelis,et al. Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis. , 2019, Journal of visualized experiments : JoVE.
[12] J. Pollard,et al. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.
[13] Oguzhan Alagoz,et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 , 2018, JAMA.
[14] T. Rohan,et al. Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population , 2017, Journal of Racial and Ethnic Health Disparities.
[15] R. Gray,et al. A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer , 2017, npj Breast Cancer.
[16] Tsonwin Hai,et al. Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis , 2017, Proceedings of the National Academy of Sciences.
[17] H. Sebastian Seung,et al. Trainable Weka Segmentation: a machine learning tool for microscopy pixel classification , 2017, Bioinform..
[18] Thomas E Rohan,et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism , 2017, Science Translational Medicine.
[19] J. Condeelis,et al. Macrophage-dependent tumor cell transendothelial migration is mediated by Notch1/MenaINV-initiated invadopodium formation , 2016, Scientific Reports.
[20] C. Blanpain,et al. Cancer Stem Cells: Basic Concepts and Therapeutic Implications. , 2016, Annual review of pathology.
[21] T. Rohan,et al. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration , 2014, Science Signaling.
[22] T. Rohan,et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. , 2014, Journal of the National Cancer Institute.
[23] G. Hortobagyi,et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[25] I. Ellis,et al. A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer , 2012, Breast Cancer Research and Treatment.
[26] E. Perez,et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. , 2012, Journal of the National Cancer Institute.
[27] J. Condeelis,et al. Mena invasive (MenaINV) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM , 2011, Clinical & Experimental Metastasis.
[28] G. Di,et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures , 2010, Breast Cancer Research and Treatment.
[29] Dawn L Hershman,et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.
[30] R. Stephens,et al. Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.
[31] J. A. van der Hage,et al. Neoadjuvant chemotherapy for operable breast cancer , 2007, The British journal of surgery.
[32] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[33] D. Nerenz,et al. Comorbidity and survival disparities among black and white patients with breast cancer. , 2005, JAMA.
[34] for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.
[35] Noam Brown,et al. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.
[36] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[37] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .
[38] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.